{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:15:57Z","timestamp":1773098157312,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction\/Aims<\/jats:title>\n Sex\u2010specific differences in myasthenia gravis (MG) are widely acknowledged, yet data on sex\u2010based outcomes of MG treatment are scarce. In accordance with Sex and Gender Equity in Research guidelines, this post hoc analysis assessed potential sex\u2010specific differences in treatment outcomes in acetylcholine receptor antibody\u2013positive (AChR\u2010Ab+) generalized (g)MG participants in the Phase 3 ADAPT trial (NCT03669588).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Participants received four once\u2010weekly efgartigimod infusions (10\u2009mg\/kg) or placebo per cycle. Endpoints (primary: proportion of Myasthenia Gravis Activities of Daily Living (MG\u2010ADL) responders (Cycle 1); secondary: proportion of Quantitative Myasthenia Gravis (QMG) and early (Cycle 1) MG\u2010ADL responders, and time with clinically meaningful improvements in MG\u2010ADL score; additional: quality of life outcomes, pharmacodynamics) were assessed according to sex.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Females were younger (mean age: 42.9 vs. 54.8\u2009years), more likely to have undergone thymectomy (65.1% [56\/86] vs. 44.2% [19\/43]), and had higher baseline QMG scores (16.3 vs. 14.3) compared with males. Efgartigimod demonstrated homogeneous effects between sexes, with no significant difference in proportions of MG\u2010ADL (\n p<\/jats:italic>\n \u2009=\u20090.7014), early (Cycle 1) MG\u2010ADL (\n p<\/jats:italic>\n \u2009=\u20091.00), or QMG responders (\n p<\/jats:italic>\n \u2009=\u20090.1595). Improvements in quality\u2010of\u2010life assessments, rates of minimal symptom expression, and mean total immunoglobulin G reductions (Cycle 1) were greater with efgartigimod verso placebo in females and males. Efgartigimod was well tolerated, with similar safety profiles across sexes.\n <\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n In ADAPT, efgartigimod\u2010treated female and male AChR\u2010Ab+ gMG patients had similar efficacy and safety outcomes. These data provide valuable insight for clinicians, given the established sex differences in MG disease course and treatment responses.<\/jats:p>\n \n Trial Registration:<\/jats:bold>\n The ADAPT trial is registered on\n ClinicalTrials.gov<\/jats:ext-link>\n (NCT03669588).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/mus.70135","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:15:11Z","timestamp":1768032911000},"page":"566-574","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post Hoc, Sex\u2010Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the\n ADAPT<\/scp>\n Trial: A Sex and Gender Equity in Research (\n SAGER<\/scp>\n ) Guidelines Approach"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-2594","authenticated-orcid":false,"given":"Sarah","family":"Hoffmann","sequence":"first","affiliation":[{"name":"Department of Neurology Neuroscience Clinical Research Center (NCRC) and Integrated Myasthenia Gravis Center, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Argenx Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Callewaert","sequence":"additional","affiliation":[{"name":"Argenx Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Schoppe","sequence":"additional","affiliation":[{"name":"Argenx Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"R\u00f3zsa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jahn Ferenc D\u00e9l\u2010Pesti Hospital Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery Queen Square University College London Hospitals (UCLH) National Health Service (NHS) Foundation Trust London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26104"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0756-3"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03406-0"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01549-z"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27331"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2017.1344237"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-016-0007-6"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_12_15_1","unstructured":"European Medicines Agency \u201cVYVGART\u00ae EU Summary of Product Characteristics \u201daccessed January 10 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/vyvgart\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_16_1","unstructured":"US Food and Drug Administration \u201cVYVGART (Efgartigimod Alfa\u2010Fcab) Injection for Intravenous Use Prescribing Information \u201dupdated October 2024 accessed January 10 2025 https:\/\/www.argenx.com\/product\/vyvgart\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_12_17_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cPrescribing Information: VYVGART (Efgartigimod Alfa\u2010Fcab) Injection for Intravenous Use \u201dupdated December 13 2021 accessed January 10 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761195s000lbl.pdf."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2017.17009"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00160"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mus.70135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.70135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:47:06Z","timestamp":1773060426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.70135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/mus.70135"],"URL":"https:\/\/doi.org\/10.1002\/mus.70135","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"2025-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}